@NamrataRheum on outcomes in RA patients on RTX who get COVID-19. ⬆️hospitalisation, ICU, mech ventilation, but not mortality (in this cohort) Abstr#1445 #ACR21 @RheumNow https://t.co/8RcrzTdEb0

#ACR21 Ab#1445. RTX & #covid19 outcomes ⭐️RTX ass. w/ ⬆️ COVID hospitalization, ICU admission, and ventilation ▶️ We need huge caution in pts that have not been vax'ed before RTX 💉💉 @Rheumnow https://t.co/6UNUVh5ZW8 https://t.co/R7jNb066m6

• https://bit.ly/3qk9MB2

Yup, another large database shows more #hospitalizations with #RheumatoidArthritis with #rituximab but NOT higher mortality in matched analysis. Abst#1445 #ACR21 @RheumNow https://t.co/9XV8iX10sA

Are you using less #rituximab in #SLE during #COVID #ACR21 @RheumNow #Lupus hub

"Baseline and routine EKGS are NOT required for SLE patients just because they are on HCQ!" - Dr. HM Belmont. "The drug has been demonized due to its use in COVID patients. We don't need to hold HCQ for EMR alerts (e.g, with cipro, SSRIs, etc)." Abstr#1743 #ACR21 @rheumnow https://t.co/5Bxavo6dRg

Anti-NETs antibodies in #COVID. 1️⃣ correlate➖ w/ SpO2/FiO2 ratio (IgG r=-0.17 IgM r=-0.30 2️⃣correlate➕ w/ ⬆️D-dimer (IgG r=0.33 IgM r=0.19 3️⃣ ⬆️ in pts requiring MV In a study of 328 pts. Probably driving complement activation! #ACR21 #Abst1430 @RheumNow https://t.co/2MCrLueTzN

Abst 1550 #acr21 @RheumNow @bryan_neel rheum pts after covid 19 vaccine: 18.9% reported SEs after the 1st dose,33.1% after 2nd dose. most frequent SEs fever, HA, fatigue & arthromyalgia. All mild&self resolved. Disease flare in 1/180 pts (0.6%) 1st dose 4/118 (3.4%) 2nd dose https://t.co/5AB5CJfYt8

FDA Update: 3 trials showing Efficacy of Tocilizumab in COVID 19: 1. RECOVERY - lower mortality 2. EMPACTA - Less progression to mech vent or death 3. REMDACTA & COVACTA - did not meet primary endpoints (but not contradictory) FDA Metanalysis of all 4 trials #ACR21 EUA 6/21 https://t.co/9yHu87KGej

FDA Update session: Proven Benefit of Baricitinib in Hospitalized COVID-19 from the ACT2 and COV-BARRIER Studies, showing it does not need to be given with Remdesivir (4 mg qd maz 14days) #ACR21 https://t.co/r6crPtu3ZH

FDA Update at #ACR21, Dr. Golding reviews the criteria for EUA - Emergency use authorization for new drugs (critically important during COVID-19) Session 8M115 https://t.co/DqmxEIdvWZ D https://t.co/6aQG8yP7RW

• https://bit.ly/301fOvh

#ACR21 #Abstr1420 A study checking #COVID vaccine response in 90 #lupus pts and 20 HC: ⬇️Titres of Abs in SLE vs controls 💠Factors of poor response: On any DMARDs exc HCQ only (OR 15) and normal dsDNA 📢Important to pause DMARDs in stable SLE @RheumNow https://t.co/USovFkiCRb https://t.co/bn5CC0xRS9

• Evaluation of SARS-CoV-2 Vaccine Response in a Multi-Racial/Ethnic Cohort of Pa…

📢#ACR21 #Abstr1421 Is #COVID19 vaccine safe and effective in #lupus? YES!! VOCOLUP study (N=1189 pts) showed: 💠~45% had a side-effect; of which 80% mild/moderate 💠Only 3% flared post💉(MSK + Fatigue); 10 required hospitalisation @RheumNow #ACRBest https://t.co/WF4aAfiX70 https://t.co/jc0HQoJymo

• Efficacy and Tolerance of Vaccination Against COVID-19 in Patients with Systemi…

#ACR21 #Abstr1083 Do pts with Autoinflammatory disease flare differently during #COVID19? Survey of N=647 (mostly CAPS): 💠56% No change 💠Of pts who flared, 50% had low/absent fever 💠7% had COVID; mostly mild Shielding could influence results @RheumNow https://t.co/g7VazLfiT9 https://t.co/lzaSoMEzyR

• Outcomes of COVID-19 Illness in Systemic Autoinflammatory Diseases and Changes …

Dr FCardwell et al on Health Info use in SLE pts b4 and during COVID19 using an online survey 🦋#lupus specialists & fam physicians - ⬆preferred & trusted health info sources but access to them ⬇frequent during covid19 A call to action?📢 @RheumNow #ACR21 abs0880 @rheumarhyme https://t.co/1NBEAlFvHx